References
- Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, . Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 2006;43:1–11.
- Heymans O, Gebhart M, Alexiou J, Sokolow Y. Camurati-Engelmann disease. Effects of corticosteroids. Acta Clin Belg 1998;53:189–92.
- Inaoka T, Shuke N, Sato J, Ishikawa Y, Takahashi K, Aburano T, . Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). Clin Nucl Med 2001;26:680–2.
- Azria M, Copp DH, Zanelli JM. 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995;57:405–8.
- Zikan V, Stepan JJ. Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 2002;316:63–9.
- Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ. Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int 2004;75:477–81.
- Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis – effects of withdrawal of treatment. Am J Med 1990;89:1–6.
- Colado MI, Ormazabal MJ, Goicoechea C, Lopez F, Alfaro MJ, Martin MI. Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur J Pharmacol 1994;252:291–7.
- Laurian L, Oberman Z, Graf E, Gilad S, Hoerer E, Simantov R. Calcitonin induced increase in ACTH, beta-endorphin and cortisol secretion. Horm Metab Res 1986;18:268–71.
- Strettle RJ, Bates RF, Buckley GA. Evidence for a direct anti-inflammatory action of calcitonin: inhibition of histamine-induced mouse pinnal oedema by porcine calcitonin. J Pharm Pharmacol 1980;32:192–5.